Kazia Therapeutics Ltd (ASX:KZA, NASDAQ:KZIA) CEO Dr James Garner tells Proactive he is encouraged by the publication in a peer-reviewed cancer research journal of positive pre-clinical data for EVT801, the company’s clinical-stage drug candidate in a trial for multiple forms of cancer. He also updates on the status and progress with the company's lead drug Paxalisib.
Kazia Therapeutics talks positive pre-clinical data for EVT801
